Benitec Biopharma (BNTC) Total Current Liabilities (2019 - 2025)

Benitec Biopharma has reported Total Current Liabilities for 7 years, with the latest figure at $2.8 million in Q4 2025.

• Quarterly Total Current Liabilities fell 9.32% year-over-year to $2.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.8 million (down 9.32% YoY) and the FY2025 annual result came in at $1.8 million, down 63.4% from the prior year.
• Total Current Liabilities climbed to $2.8 million in Q4 2025 per BNTC's latest filing, from $2.0 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $7.0 million in Q1 2025 and troughed at $1.4 million in Q2 2021.
• A 5-year average of $3.2 million and a median of $2.9 million in 2022 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2021 and 2025: Total Current Liabilities surged 218.36% in 2021, then slumped 63.4% in 2025.
• Over 5 years, Total Current Liabilities stood at $2.5 million in 2021, then grew by 0.36% to $2.5 million in 2022, then jumped by 130.86% to $5.7 million in 2023, then sank by 46.24% to $3.1 million in 2024, then dropped by 9.32% to $2.8 million in 2025.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $2.8 million, $2.0 million, and $1.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.